MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.555
-0.235
-8.42%
Opening 15:15 09/23 EDT
OPEN
2.790
PREV CLOSE
2.790
HIGH
2.840
LOW
2.520
VOLUME
8.54M
TURNOVER
--
52 WEEK HIGH
13.71
52 WEEK LOW
2.460
MARKET CAP
360.90M
P/E (TTM)
-0.8495
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Akebia Therapeutics Announces September 2020 Investor Conference Schedule
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the following virtual investor conferences in September.
PR Newswire · 09/08 12:00
Akebia Anemia Data, And Other News: The Good, Bad And Ugly Of Biopharma
Akebia reports data for its anemia drug candidate.Abbott moves ahead with Drug-Eluting resorbable scaffold.Savara announces discontinuing Molgradex for NTM lung infection.
Seekingalpha · 09/07 03:16
Akebia Falls as Vadadustat Fails to Meet Safety Endpoint
Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.
Zacks · 09/04 16:55
Morgan Stanley Maintains Equal-Weight on Akebia Therapeutics, Lowers Price Target to $3
Morgan Stanley maintains Akebia Therapeutics (NASDAQ:AKBA) with a Equal-Weight and lowers the price target from $12 to $3.
Benzinga · 09/04 12:34
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho
AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 09/04 10:22
Mid-Afternoon Market Update: Nasdaq Tumbles 575 Points; PagerDuty Shares Tumble On Weak Outlook
Toward the end of trading Thursday, the Dow traded down 2.79% to 28,287.97 while the NASDAQ fell 4.77% to 11,481.59. The S&P also fell, dropping 3.44% to 3,457.82.
Benzinga · 09/03 18:31
Mid-Day Market Update: Dow Tumbles Over 500 Points; Fulgent Genetics Shares Jump
Midway through trading Thursday, the Dow traded down 1.87% to 28552.13 while the NASDAQ fell 4.07% to 11,565.74. The S&P also fell, dropping 2.66% to 3,485.59.
Benzinga · 09/03 16:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKBA. Analyze the recent business situations of Akebia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKBA stock price target is 6.86 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 247
Institutional Holdings: 114.53M
% Owned: 81.08%
Shares Outstanding: 141.25M
TypeInstitutionsShares
Increased
75
15.92M
New
61
10.45M
Decreased
43
7.74M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.37%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Independent Director
Adrian Adams
President/Chief Executive Officer/Director
John Butler
Chief Financial Officer/Senior Vice President/Treasurer
David Spellman
Chief Operating Officer/Senior Vice President
Michel Dahan
Senior Vice President/Secretary
Nicole Hadas
Senior Vice President
Steven Burke
Senior Vice President
Dell Faulkingham
Independent Director
Mark Enyedy
Independent Director
Steven Gilman
Independent Director
Maxine Gowen
Independent Director
Michael Heffernan
Independent Director
Michael Rogers
Independent Director
Cynthia Smith
Independent Director
Myles Wolf
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.